Early survival data boost Ziopharm's 'controlled IL-12' immunotherapy for glioblastoma

Early survival data boost Ziopharm's 'controlled IL-12' immunotherapy for glioblastoma

Source: 
Endpoints
snippet: 

An unconventional pairing of a gene therapy and an oral drug that promises to attack recurrent or progressive glioblastoma with controlled release of IL-12 has turned up more promising — if early — overall survival data. On top of boosting its case as a monotherapy, the data can also bode well for a combination with Regeneron’s PD-1 inhibitor, Libtayo.